Geneoscopy

• ·Geneoscopy’s last known valuation is $440.0M (Jan 2025).
• ·It has raised $218.4M across 2 recorded rounds; the latest was Later Stage VC ($50.5M) in May 2021.
• ·Notable investors include Dorm Room Fund, Morningside Group, Cultivation Capital, Labcorp Venture Fund, iSelect Fund — 24 tracked in total.
• ·1 investment vehicle was formed to buy Geneoscopy shares in the last 12 months, reporting $802K sold to 22 investors, per SEC Form D filings.
• ·Geneoscopy has filed 2 Form Ds with the SEC since 2019, most recently Nov 2021 ($50.5M sold to 85 investors).
• ·Status: Privately Held (backing).

In the last 12 months, 1 investment vehicle were formed to buy Geneoscopy shares, reporting $802K sold to 22 investors. Most recent filing Jan 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.

Developer of a molecular diagnostic platform designed to prevent, detect, and monitor gastrointestinal diseases through noninvasive testing. The company's platform offers stool-derived eukaryotic RNA technology with molecular analysis of gastrointestinal biology, enabling healthcare providers to access safer, more convenient disease screening and monitoring that supports earlier detection and informed care decisions.

Sector

Healthcare

HQ

Saint Louis, MO, United States

Founded

2015

Employees

67

Website

geneoscopy.com/

Ownership

Privately Held (backing)